Jeffrey W. Albers - Net Worth and Insider Trading

Jeffrey W. Albers Net Worth

The estimated net worth of Jeffrey W. Albers is at least $16 Million dollars as of 2024-04-28. Jeffrey W. Albers is the Director of Blueprint Medicines Corp and owns about 176,050 shares of Blueprint Medicines Corp (BPMC) stock worth over $16 Million. Jeffrey W. Albers is also the Director of Kymera Therapeutics Inc and owns about 0 shares of Kymera Therapeutics Inc (KYMR) stock worth over $0. Details can be seen in Jeffrey W. Albers's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jeffrey W. Albers has not made any transactions after 2024-03-20 and currently still holds the listed stock(s).

Transaction Summary of Jeffrey W. Albers

To

Jeffrey W. Albers Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jeffrey W. Albers owns 3 companies in total, including Blueprint Medicines Corp (BPMC) , Kymera Therapeutics Inc (KYMR) , and Magenta Therapeutics Inc (MGTA) .

Click here to see the complete history of Jeffrey W. Albers’s form 4 insider trades.

Insider Ownership Summary of Jeffrey W. Albers

Ticker Comapny Transaction Date Type of Owner
BPMC Blueprint Medicines Corp 2024-03-20 director & CEO & President
KYMR Kymera Therapeutics Inc 2024-02-21 director
MGTA Magenta Therapeutics Inc 2018-06-20 director

Jeffrey W. Albers Latest Holdings Summary

Jeffrey W. Albers currently owns a total of 2 stocks. Among these stocks, Jeffrey W. Albers owns 176,050 shares of Blueprint Medicines Corp (BPMC) as of March 20, 2024, with a value of $16 Million and a weighting of 100%. Jeffrey W. Albers also owns 0 shares of Kymera Therapeutics Inc (KYMR) as of February 21, 2024, with a value of $0 and a weighting of 0%.

Latest Holdings of Jeffrey W. Albers

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BPMC Blueprint Medicines Corp 2024-03-20 176,050 93.00 16,372,650
KYMR Kymera Therapeutics Inc 2024-02-21 0 33.37 0

Holding Weightings of Jeffrey W. Albers


Jeffrey W. Albers Form 4 Trading Tracker

According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 31 transactions in Blueprint Medicines Corp (BPMC) over the past 5 years, including 0 buys and 31 sells. The most-recent trade in Blueprint Medicines Corp is the sale of 25,073 shares on March 20, 2024, which brought Jeffrey W. Albers around $2 Million.

According to the SEC Form 4 filings, Jeffrey W. Albers has made a total of 2 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Kymera Therapeutics Inc is the sale of 5,000 shares on February 21, 2024, which brought Jeffrey W. Albers around $195,250.

Insider Trading History of Jeffrey W. Albers

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jeffrey W. Albers Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jeffrey W. Albers Ownership Network

Ownership Network List of Jeffrey W. Albers

No Data

Ownership Network Relation of Jeffrey W. Albers


Jeffrey W. Albers Owned Company Details

What does Blueprint Medicines Corp do?

Who are the key executives at Blueprint Medicines Corp?

Jeffrey W. Albers is the director & CEO & President of Blueprint Medicines Corp. Other key executives at Blueprint Medicines Corp include Principal FAO Michael Landsittel , Principal Accounting Officer Ariel Hurley , and Chief Commercial Officer Philina Lee .

Blueprint Medicines Corp (BPMC) Insider Trades Summary

Over the past 18 months, Jeffrey W. Albers made 11 insider transaction in Blueprint Medicines Corp (BPMC) with a net sale of 175,899. Other recent insider transactions involving Blueprint Medicines Corp (BPMC) include a net sale of 11,217 shares made by Christopher K. Murray , a net sale of 26,744 shares made by Michael Landsittel , and a net sale of 7,851 shares made by Ariel Hurley .

In summary, during the past 3 months, insiders sold 118,534 shares of Blueprint Medicines Corp (BPMC) in total and bought 0 shares, with a net sale of 118,534 shares. During the past 18 months, 301,340 shares of Blueprint Medicines Corp (BPMC) were sold and 1,100 shares were bought by its insiders, resulting in a net sale of 300,240 shares.

Blueprint Medicines Corp (BPMC)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Blueprint Medicines Corp Insider Transactions

No Available Data

Jeffrey W. Albers Mailing Address

Above is the net worth, insider trading, and ownership report for Jeffrey W. Albers. You might contact Jeffrey W. Albers via mailing address: Blueprint Medicines Corp., 215 First Street, Suite 340/350, Cambridge Ma 02142.

Discussions on Jeffrey W. Albers

No discussions yet.